Free Trial
NASDAQ:CRSP

CRISPR Therapeutics Q4 2024 Earnings Report

CRISPR Therapeutics logo
$53.05 -0.48 (-0.90%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$53.28 +0.23 (+0.44%)
As of 08/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics EPS Results

Actual EPS
-$0.44
Consensus EPS
-$1.15
Beat/Miss
Beat by +$0.71
One Year Ago EPS
N/A

CRISPR Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CRISPR Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Tuesday, February 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

CRISPR Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CRISPR Therapeutics Earnings Headlines

Crispr Therapeutics AG (CRSP) Has a New Rating from Evercore ISI
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Crispr Therapeutics: Sell Before It's Too Late
See More CRISPR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics (NASDAQ:CRSP) is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

View CRISPR Therapeutics Profile

More Earnings Resources from MarketBeat